Levels of y-Aminobutyric Acid in Cerebrospinal Fluid in Various Neurologic Disorders
Arch Neurol 37:352-355, Manyam,N.V.B.,et al, 1980
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Longitudinal Change in Basal Ganglia Volume in Patients with Huntington's Disease
Neurol 48:394-399, Aylward,E.H.,et al, 1997
Reduced Basal Ganglia Volume Associated with the Gene for Huntington's Disease in Asymptomatic at-Risk Persons
Neurol 44:823-828, Aylward,E.H.,et al, 1994
Molecular Basis of the Neurodegenerative Disorders
NEJM 340:1970-1980, Martin,J.B., 1999
The Molecular Genetic Revolution, Its Impact on Clinical Neurology
Arch Neurol 45:1366-1376, Payne,C.S.&Roses,A.D., 1988
Neuropeptides in Neurological Disease
Ann Neurol 20:547-565, Beal,M.F.&Martin,J.B., 1986
Huntington's Disease, CSF GABA Level in at-risk Individuals
Arch Neurol 35:728-730, Manyam,N.V.B.,et al, 1978
Identification of GABA in Human CSF by Gas Liquid Chromatography & Mass Spectrometry
NEJM 296:692, Huizinga,J.D.,et al, 1977
Treatment of Huntington's Chorea with Isoniazid
NEJM 297:840, 1977. (Letter), Perry,T.L.,et al, 1977
Clinical Diagnosis of the Dyskinesias
Med Clin of North Am 56:1321, Duvoisin,R., 1972